Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Choong Kim

Showing results (161-170 of 172) with videos related to

Pageof 18
Sort By:
Life Sciences|March 27, 2007
Nodakenin, a coumarin compound, ameliorates scopolamine-induced memory disruption in miceDong Hyun Kim, Do Yoon Kim, Young Choong Kim, et al.
Oncotarget|November 16, 2017
Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resectionMi Jung Kwon, Kab-Choong Kim, Eun Sook Nam, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|June 15, 2016
ESP-102, a Combined Herbal Extract of Angelica gigas, Saururus chinensis, and Schisandra chinensis, Changes Synaptic Plasticity and Attenuates Scopolamine-Induced Memory Impairment in Rat Hippocampus TissueHyun-Bum Kim, Eun-Sang Hwang, Ga-Young Choi, et al.
Cancer Chemotherapy and Pharmacology|August 7, 2012
Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancerJae Ho Jeong, Min-Hee Ryu, Baek-Yeol Ryoo, et al.
Journal of Cancer|June 21, 2021
RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancerSung-Hwa Sohn, Hee Jung Sul, Bohyun Kim, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2013
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinomaInkeun Park, Min-Hee Ryu, Yoon Hee Choi, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2016
A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancerBoram Han, Joo Young Jung, Hyeong Su Kim, et al.
Scandinavian Journal of Gastroenterology|June 23, 2017
Is it beneficial to perform surgical resection in elderly patients more than 80 years old with advanced gastric cancer?Jin Woo Choo, Yeonmi Ju, Hyun Lim, et al.
Gastrointestinal Endoscopy|September 6, 2011
Clinical impact of EUS-guided Trucut biopsy results on decision making for patients with gastric subepithelial tumors ≥ 2 cm in diameterJeong Hoon Lee, Kee Don Choi, Mi-Young Kim, et al.
Journal of Clinical Gastroenterology|May 28, 2011
Predictors of recurrence after resection of small gastric gastrointestinal stromal tumors of 5 cm or lessMi-Young Kim, Young Soo Park, Kee Don Choi, et al.
Pageof 18

Showing results (161-170 of 172) with videos related to

Sort By:
Pageof 18
Life Sciences|March 27, 2007
Nodakenin, a coumarin compound, ameliorates scopolamine-induced memory disruption in miceDong Hyun Kim, Do Yoon Kim, Young Choong Kim, et al.
Oncotarget|November 16, 2017
Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resectionMi Jung Kwon, Kab-Choong Kim, Eun Sook Nam, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|June 15, 2016
ESP-102, a Combined Herbal Extract of Angelica gigas, Saururus chinensis, and Schisandra chinensis, Changes Synaptic Plasticity and Attenuates Scopolamine-Induced Memory Impairment in Rat Hippocampus TissueHyun-Bum Kim, Eun-Sang Hwang, Ga-Young Choi, et al.
Cancer Chemotherapy and Pharmacology|August 7, 2012
Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancerJae Ho Jeong, Min-Hee Ryu, Baek-Yeol Ryoo, et al.
Journal of Cancer|June 21, 2021
RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancerSung-Hwa Sohn, Hee Jung Sul, Bohyun Kim, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2013
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinomaInkeun Park, Min-Hee Ryu, Yoon Hee Choi, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2016
A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancerBoram Han, Joo Young Jung, Hyeong Su Kim, et al.
Scandinavian Journal of Gastroenterology|June 23, 2017
Is it beneficial to perform surgical resection in elderly patients more than 80 years old with advanced gastric cancer?Jin Woo Choo, Yeonmi Ju, Hyun Lim, et al.
Gastrointestinal Endoscopy|September 6, 2011
Clinical impact of EUS-guided Trucut biopsy results on decision making for patients with gastric subepithelial tumors ≥ 2 cm in diameterJeong Hoon Lee, Kee Don Choi, Mi-Young Kim, et al.
Journal of Clinical Gastroenterology|May 28, 2011
Predictors of recurrence after resection of small gastric gastrointestinal stromal tumors of 5 cm or lessMi-Young Kim, Young Soo Park, Kee Don Choi, et al.
Pageof 18